Comorbidity Profile of Head and Neck Cancer Patients With and Without Depression by Frenzel, Michaela
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Capstone Experience Master of Public Health 
8-2019 
Comorbidity Profile of Head and Neck Cancer Patients With and 
Without Depression 
Michaela Frenzel 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/coph_slce 
 Part of the Mental Disorders Commons, Psychiatric and Mental Health Commons, Public Health 
Commons, and the Substance Abuse and Addiction Commons 
Recommended Citation 
Frenzel, Michaela, "Comorbidity Profile of Head and Neck Cancer Patients With and Without Depression" 
(2019). Capstone Experience. 90. 
https://digitalcommons.unmc.edu/coph_slce/90 
This Capstone Experience is brought to you for free and open access by the Master of Public Health at 
DigitalCommons@UNMC. It has been accepted for inclusion in Capstone Experience by an authorized 
administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
Comorbidity Profile of Head and Neck Cancer Patients With and Without Depression 
Abstract 
 This population-based retrospective study used SEER-Medicare data from 2002-2010 to 
assess depression, comorbidity, and substance use in the elderly head and neck cancer 
population. Out of 3,533 head and neck cancer patients, 10.6% had depression diagnoses two 
years prior to cancer diagnosis, 8.9% were newly diagnosed with depression within one year 
after cancer diagnosis, and 44.5% of those with preexisting depression had an additional 
depression diagnosis within one year following cancer diagnosis. Comorbid conditions 
(p<0.0001) and substance use (p=0.0017) showed associations with depression prior to cancer 
diagnosis yet, no significant associations with incidence of depression in this head and neck 
cancer population. This study affirms the need for continual depression screenings in head and 
neck cancer patients and suggests the need for increased research into the burden of comorbid 
conditions and substance use within the head and neck cancer population.  
Chapter 1 – Introduction 
Head and neck cancers are a group of cancers 
within certain areas of the body, such as oral cavity, 
pharynx, larynx, nasal cavity, and paranasal sinuses. 
Although not the most common type of cancer, head 
and neck cancers account for about 4% of all cancers 
in the United States (American Society of Clinical 
Oncology (ASCO), 2017; National Cancer Institute 
NCI, 2017 
(NCI), 2017). Each year, approximately 63,000 people are diagnosed with head and neck cancer, 
with diagnoses primarily occurring in individuals over the age of 50 (ASCO, 2017). It is estimated 
that about 14,000 people die each year from head and neck cancers, with men being 2-3 times 
more likely than women to develop these cancers (ASCO, 2017).  
The 5-year survival rate for head and neck cancers vary greatly, ranging from 35-80%, 
and mainly depend on location of cancer and stage of diagnosis, with an average 5-year survival 
rate across all locations of about 60% (ASCO, 2017). Later stage diagnosis is often associated 
with preexisting depression for cancer patients along with poorer survival rates and less 
definitive treatments (Baillargeon et al., 2011; Boyd et al., 2012). Depression following 
diagnosis is also associated with advanced stages of cancer and is highly prevalent in elderly 
populations (Spoletini et al., 2008; Parpa, Tsilika, Gennimata, & Mystakidou, 2015). Higher rates 
of depression are common in head and neck cancer patients, often related to disfigurement or 
dysfunctional eating and communication abilities, and depressive symptoms have been 
associated with lower survival rates (Haisfield-Wolfe, 2009; Zimmaro et al., 2018). Additionally, 
comorbidities are known to affect treatment plans for head and neck cancer patients and the 
severity of comorbidities has been associated with poorer outcomes and lower survival rates in 
this population (Piccirillo, 2000).   
Since patients diagnosed with head and neck cancer are particularly at risk for 
depression and other comorbidities before and after cancer diagnosis, it is important to 
understand the associations between additional comorbidities and depression in this 
population. However, little has been shown in the literature aimed at analyzing these 
connections. The purpose of this research report is to examine the associations between 
comorbidities and depression status in patients with head and neck cancers using the 
Surveillance, Epidemiology and End Results (SEER)-Medicare linked data. The specific aims of 
this study are to: (1) estimate the prevalence of depression and common comorbidities before 
cancer diagnosis, (2) estimate the incidence of depression 1 year after cancer diagnosis, (3) 
compare comorbidity distributions between patients with and without depression, and (4) 
examine common comorbidities and other factors associated with prevalence and incidence of 
depression.  
Chapter 2 – Background and Literature Review 
Overall, head and neck cancers have been known to be more emotionally taxing than 
other cancer types (Koster & Bergsma, 1990). Often associated with a higher prevalence of 
depression compared to other cancers, patients with head and neck cancer share many risk 
factors between the two diseases. The most notable shared risk factors for depression and 
head and neck cancer are excessive tobacco and/or alcohol use and poor lifestyle choices, 
including unhealthy diet. Such shared risk factors create higher risk for this cancer population to 
develop depression after diagnosis along with having an increased risk for depression prior to 
diagnosis. Additionally, negative impacts of head and neck cancer often result from the location 
of cancer near the face and the treatment process. Patients may experience severe 
disfigurement related to the cancer itself or due to the treatment process which can impact 
physical and mental health (Massie et al., 2011). Patients may also experience distress from 
issues such as eating, breathing, and communication which may be affected in this cancer 
population (Haisfield-Wolfe, 2009). Treatment options often include the use of radiation 
therapy which has been associated with increased psychiatric disorders, including depression, 
which can greatly affect patient outcomes (Frick, 2007; Kelly et al., 2007).  
Since head and neck cancers are typically diagnosed in individuals over the age of 50, it 
is more likely comorbidities play a role in patient outcomes. Prevalence of comorbidity 
increases with age and is known to impact treatment and treatment selection in head and neck 
cancer patients (Boje, 2014). Within populations of older adults aged 65 years or older, 
hypertension, hyperlipidemia, heart disease, arthritis, and diabetes are some of the most 
prevalent comorbid conditions, which are similarly seen in cancer populations (Williams et al., 
2016). Higher rates of comorbidity have been observed in patients with head and neck cancer 
in particular and additional diseases create difficulties when selecting treatment modalities, 
thus affecting outcomes. Previous research has shown hypertension, pulmonary disease, 
diabetes to be highly prevalent in the head and neck cancer population, with prevalence of 
28%, 13%, and 10%, respectively (Piccirillo & Vlahiotis, 2006). Such comorbid diseases are 
consistent with elderly populations, with higher impacts on those with head and neck cancer as 
an added disease. Additionally, high amounts of comorbidity and increased severity are known 
to increase mortality and have dramatic impacts on patient quality of life, especially for elderly 
cancer populations (Piccirillo & Vlahiotis, 2006; Williams et al., 2016; Paleri et al., 2010).  
Substance use disorders are a highly prevalent comorbidity among patients with cancer, 
especially for head and neck cancer patients. Tobacco and alcohol use are well known risk 
factors for developing head and neck cancer and many patients continue use following 
diagnosis (Hashibe et al., 2009).  Previous research has shown that in patients diagnosed with 
head and neck cancer over 30% continue to smoke and 16% continue hazardous alcohol 
consumption, despite major impacts on treatment and quality of life related to depression 
(Duffy et al., 2007). Use of other substances have also been shown to be strongly associated 
with depression (Swendsen, J. D. & Merikangas, K. R., 2000; Moussas, G. I. & Papadopoulou, A. 
G., 2017). However, less is known about related impacts on cancer due to large numbers of 
drug subtypes and complications in research related to polysubstance use.  
Implications of depression, substance use and additional comorbidities in head and neck 
cancer patients can be serious. Individuals with head and neck cancer have been shown to have 
higher risk for suicide compared to patients with other cancers and the general population 
(Zeller, 2006) while other studies have shown associations between mental illness, such as 
depression, and fewer cancer screenings, leading to later stage diagnosis (Baillargeon et al., 
2011; Boyd et al., 2012). Differences in survival rates have been noted by recent studies for 
head and neck cancer patients with severe comorbidity conditions as well as more negative 
outcomes for individuals with an increased number of comorbidities (Boje, 2014; Yang & 
Warnakulasuriya, 2016). Substance use, especially alcohol and tobacco abuse, are known risk 
factors of head and neck cancer while being highly associated with mood disorders, like 
depression (Lai, Cleary, Sitharthan & Hunt, 2015; Duffy et al., 2007) However, even with the 
known impacts of depression, substance use, and other comorbidities, there are gaps in the 
research concerning the additive effects of substance use and other comorbid conditions on 
depression in head and neck cancer populations. 
Chapter 3 – Data and Methods 
This was a population-based retrospective study that used records from the SEER-
Medicare database from 2002-2010. The SEER-Medicare linked database utilizes two large 
population-based sources of data to provide information on elderly adults with cancer 
diagnoses (NCI, 2019). The SEER database provides clinical, demographic, and death 
information on cancer patients while the Medicare databased provides information on claims 
for health care services provided while the patient was using Medicare insurance (NCI, 2019). 
From the database, the records of more than 10,000 individuals diagnosed with head and neck 
cancer in 2004-2005 were analyzed and those meeting certain criteria were included in the 
study sample.  
For inclusion in the study sample, patients had to have head and neck cancer as their 
only cancer diagnosis and be aged 67 years or older, to guarantee at least two years of 
Medicare enrollment prior to cancer diagnosis (Figure 1). Additionally, patients could not be 
enrolled in a health maintenance organization (HMO) during the two years prior or one year 
following diagnosis along with continual enrollment in Medicare Parts A and B for two years 
before their cancer diagnosis, to ensure complete claim records. Head and neck cancer 
diagnosis was identified using International Classification of Disease for Oncology, Version 3 
codes (ICD-O3) for lip, oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx cancers. 
The study sample was further separated by depression status using ICD-9-CM codes for 
depression, including: dysthymic disorder, major depression (single or recurrent episode), 
adjustment disorder (with depressive symptoms or prolonged depressive reaction), depressive 
disorder (not otherwise classified), bipolar I disorder (most recent episode or current 
depressed), depressive type psychosis, affective personality disorder (unspecified), chronic 
depressive personality disorder, and cyclothymic disorder. Preexisting depression groups, post-
cancer diagnosis depression groups, and a preexisting cancer with additional post-cancer 
depression diagnosis groups were created. Preexisting depression was defined as those with at 
least one depression diagnosis within two years prior to their cancer diagnosis. Post-cancer 
diagnosis depression was defined at least one depression diagnosis within one year following 
cancer diagnosis and those with preexisting depression were excluded. Preexisting depression 
with additional post-cancer depression diagnosis was defined as those having preexisting 
cancer and at least one addition diagnosis of depression following cancer diagnosis. For all 
analyses on the post-cancer diagnosis depression group, individuals diagnosed with head and 
neck cancers at death or autopsy were excluded since depression could not develop.  
Sociodemographic information (sex, race, age, education, income, marital status, and 
cancer stage) was taken from SEER data with education and income based on census tract. 
Comorbidity diagnoses were determined using ICD-9-CM diagnostic codes based on the Deyo 
method for Medicare data (Deyo, Cherkin, & Ciol, 1992). Claims were used for diagnoses twelve 
months prior to head and neck cancer diagnosis and included myocardial infarction, congestive 
heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic 
obstructive pulmonary disease, rheumatologic disease, peptic ulcer disease, mild live disease, 
diabetes (complicated and non-complicated), hemiplegia/paraplegia, moderate to severe renal 
disease, moderate-severe liver disease, and AIDS. Diagnoses of moderate to severe liver disease 
and AIDS were included for sample demographics but were excluded from final analyses due to 
extremely low frequencies within the study sample. Comorbidity groups were defined by the 
number of unique comorbidity types each patient had based on the separated comorbidities 
listed above. Groups were divided into those with no comorbid conditions, one comorbidity 
type, two comorbidity types, three comorbidity types, and four or more comorbidity types.  
Substance use disorder status was determined using Medicare data based on ICD-9-CM 
diagnostic codes. The codes included diagnoses for alcohol induced mental disorders, drug 
induced mental disorders, alcohol dependence, drug dependence, and non-dependence drug 
abuse (including tobacco use). Substance use was categorized by drug use type into alcohol use, 
tobacco use, and all other drugs.  
Chi-square tests were used to determine differences in demographics between 
depression status groups, before and after cancer diagnosis. Further chi-square tests were used 
to determine differences in frequency of comorbid conditions and substance use disorders 
between depression status groups, before and after cancer diagnosis. Additional analysis of 
factors associated with depression diagnosis were completed with multivariable logistic 
regression models using stepwise selection. All analyses were completed using SAS version 9.4.  
Chapter 4 – Results 
A total of 12,175 patients were diagnosed with head and neck cancer from 2004-2005. 
From these individuals, 2,951 were excluded due to additional cancer diagnoses, 4,315 were 
excluded for age of diagnosis below 67 years, 151 were excluded for lacking continuous 
enrollment in Medicare Parts A and B, and 1,225 were excluded for enrollment in an HMO at 
some point during the study. The final sample included 3,533 patients.  
Depression prior to cancer diagnosis. Of the 3,533 patients, 375 (10.6%) patients were 
diagnosed with depression within two years prior to head and neck cancer diagnosis. Table 1 
provides demographics of these individuals by depression status prior to head and neck cancer 
diagnosis. These groups had significant differences by age, gender, race, marital status, and 
number of unique comorbidities. The preexisting depression group had a higher percentage of 
patients in the two oldest age group, 80-84: (18.7% vs 15.3%) and 85+: (16.3% vs 12.9%), and a 
lower percentage of patients in the youngest age group, 67-69: (16.3% vs 21.3%). Additionally, 
the preexisting depression group had a higher percentage of females (45.9% vs 32.5%) and 
Non-Hispanic whites (86.9% vs 80.2%), compared to the non-depressed group. Differences in 
marital status were seen between the groups such that the preexisting depression group had a 
higher percentage of widowed patients (34.1% vs 24.5%) and a lower percentage of married or 
living as married patients (40.5% vs 52%). The number of unique comorbidities was different 
between depression groups such that patients with preexisting depression had a higher 
percentage of patients with more comorbidity types. The preexisting depression group had a 
higher percentage of patients with 4 or more comorbidity types (24.8% vs 9.5%) and a lower 
percentage of patients with no comorbid conditions (18.4% vs 37.6%). For those 375 individuals 
with preexisting depression, 267 (44.5%) had an additional depression diagnosis following head 
and neck cancer diagnosis.  
Comorbidity comparison by depression status prior to cancer diagnosis. Table 2 
provides the comorbidity characteristics of the study sample by depression status prior to head 
and neck cancer diagnosis. The preexisting depression group had a significantly higher 
percentage of individuals with each comorbidity category, except moderate to severe liver 
disease and AIDS, which were about equal between preexisting depression and non-depression 
groups. Table 2a provides the distribution of substance use disorders in the sample prior to 
cancer diagnosis. The groups differed significantly by alcohol use, with a higher percentage of 
alcohol users in the preexisting depression group (8.3% vs 4.7%). Both groups had similar 
percentages of individuals using tobacco. Additionally, there was a trending difference in use of 
other drugs with a slightly higher percentage other drug users in the preexisting depression 
group (1.1% vs 0.4%).  
Multivariable logistic regression of factors associated with preexisting depression. The 
odds of having depression compared to no depression prior to cancer diagnosis differs 
significantly by gender, race/ethnicity, number of comorbidities, and alcohol use (Table 3). 
Females have 1.88 (95% CI=1.50, 2.35) times the odds of having preexisting depression 
compared to males after adjusting for all other variables in the model. Non-white individuals 
have 0.57 (95% CI=0.41, 0.79) times the odds of having preexisting depression compared to 
Non-Hispanic Whites after adjusting for other variables in the model. Additionally, increasing 
the number of comorbidities is associated with increasing odds of preexisting depression such 
that one additional comorbidity has 1.28 (95% CI=0.91, 1.81) times the odds, two additional 
comorbidities have 2.51 (95% CI=1.78, 3.55) times the odds, three additional comorbidities 
have 3.79 (95% CI=2.63, 5.46) times the odds, and four or more additional comorbidities have 
5.32 (95% CI=3.78, 7.49) times the odds after adjusting for other model variables. Finally, 
alcohol use was associated with preexisting depression such that individuals using alcohol had 
1.97 (95% CI=1.29, 3.01) time the odds of preexisting depression when compared to those not 
using alcohol after adjusting for other model variables. No significant associations were found 
with interactions between gender, race/ethnicity, comorbidity group, and alcohol. 
Additional depression diagnosis following cancer diagnosis. A further analysis was 
conducted on the sample of 375 patients who had preexisting depression. During the one-year 
period following head and neck cancer diagnosis, 167 or 44.5% received at least one additional 
depression diagnosis. Table 4 compares demographics of patients with additional depression 
diagnosis (n=167) and patients without additional depression diagnosis (n=208). These groups 
differ by race/ethnicity, with a higher percentage of Non-Hispanic Whites in the depression 
group (92.8% vs 82.2%). Table 5 compares the comorbidity characteristics of these two 
samples. These groups have significant difference in prevalence of myocardial infarction, non-
complicated diabetes, and moderate to severe renal disease. Individuals with an additional 
diagnosis of depression have a lower percentage of myocardial infarction (5.4% vs 12.5%), a 
lower percentage of non-complicated diabetes (23.4% vs 33.2%) and a lower percentage of 
moderate to severe renal disease (6.0% vs 13.0%). Table 5a provides the distribution of 
substance use disorders for patients with preexisting depression by status of additional 
depression diagnoses following cancer diagnosis. These groups have no significant differences 
in alcohol, tobacco, or other drug use.  
New depression case development following cancer diagnosis. There were 3,158 
patients who had no depression diagnosis during the two years before head and neck cancer 
diagnosis. Within one year after the head and neck cancer diagnosis, 281 (8.9%) developed 
depression. Table 6 provides demographics of these individuals by depression status following 
cancer diagnosis. These groups differed significantly by age and gender. The depression group 
had a higher percentage of females (40.6% vs 31.7%) compared to the non-depressed group 
and a higher percentage of patients aged 70-74 (35.2% vs 27.8%).  
Comorbidity comparison by depression status following cancer diagnosis. Table 7 
provides the comorbidity characteristics of the study sample by depression status following 
head and neck cancer diagnosis. There were no significant differences between groups on any 
comorbidity categories. Table 7a provides the substance use characteristics by depression 
status following head and neck cancer diagnosis. Trending differences were shown for other 
drug use with a slightly higher percentage of depressed patients using other drugs (1.1% vs 
0.3%). There were no significant differences between groups for alcohol or tobacco use 
following cancer diagnosis.  
Multivariable logistic regression for factors associated with new depression 
development. Gender was significantly associated with depression following cancer diagnosis 
with females having 1.49 (95% CI=1.15, 1.92) times the odds of developing depression 
compared to males, when adjusting for age (Table 8). Additionally, age was associated with 
depression following cancer diagnosis with those aged 70-74 having 1.43 (95% CI: 1.01, 2.04) 
times the odds of developing depression compared to those aged 67-69, when adjusting for 
gender. No significant interactions were found between age and gender.  
Chapter 5 – Discussion 
 The results of this study show the prevalence of depression to be approximately 10.6% 
for elderly adults during the two years prior to head and neck cancer diagnosis. Similar studies 
have shown slightly lower prevalence of depression for other cancers such as pancreatic 
adenocarcinoma (7.9%), breast cancer (7.5%), and prostate cancer (5%), suggesting a higher 
burden of depression on head and neck cancer populations (Boyd et al., 2012; Goodwin, Zhang, 
& Ostir, 2004; Prasad et al., 2014). Our findings replicate previous research results showing 
incidence rates of depression ranging from 15% to 50% in head and neck cancer populations, 
which is among the highest rates for cancer patients (Lydiatt, Moran & Burke, 2009). We found 
that one in ten patients (8.9%) with no depression diagnosis during the two years prior to head 
and neck cancer diagnosis received a diagnosis of depression within one year following cancer 
diagnosis. Interestingly, close to half (44.5%) of patients with pre-existing depression received 
additional diagnosis of depression within one year following cancer diagnosis.  
These results indicate an increased need for depression screening following cancer 
diagnosis, especially in patients known to have depressive symptoms prior to head and neck 
cancer diagnosis. Depression is a highly recurrent disorder and cancer diagnosis can be 
considered a stressful life event, creating higher risk of depressive disorders (Burcusa & Iacono, 
2007). Following diagnosis with head and neck cancer, patients with a history of depression 
may need symptoms monitored closely to avoid missed depression diagnoses which could be 
overlooked as normal grief. Focusing on such symptoms can hopefully minimize the impact of 
depression on treatment and overall quality of life in this population.  
 The present study showed high prevalence of comorbidity in the head and neck cancer 
patient sample. The overall prevalence of comorbidity was 64.5% with 62.4% of patients with 
preexisting depression having at least two types of comorbidity and 34.1% of patients without 
preexisting depression having at least two types of comorbidity. Since only unique comorbidity 
types were used in this sample, these percentages are likely a conservative measure of the 
burden of comorbidity on this population. However, the increased burden is notable and 
follows previous research showing associations between high rates of comorbidity and 
depression in elderly cancer populations (Spoletini et al., 2008).  
More specifically, the comorbidities with the highest prevalence for this sample were 
chronic obstructive pulmonary disease (32.8%), non-complicated diabetes (22.8%), peripheral 
vascular disease (19.1%), cerebrovascular disease (17.9%), and chronic heart failure (16.1%). As 
expected, patients with preexisting depression had higher percentages of most comorbidity 
types, however, patients developing depression after head and neck cancer diagnosis showed 
no difference in types of comorbidities compared to those who did not develop depression. 
Since comorbid conditions did not differ between patients that did and did not develop 
depression following head and neck cancer diagnosis, other factors likely had greater influence 
on a patient’s likelihood of developing depression. For those patients without preexisting 
depression, gender and age were the only significant predictors of depression which suggests 
other factors may be better for predicting depression in this sample. Since age and gender have 
previously been shown to be risk factors for depression across many populations, it’s possible 
that other factors have greater predictive abilities within this sample that were not assess in 
this study.  
The present study found prevalence of alcohol use disorder to be 5.0% for head and 
neck cancer patients. Previous research has shown the overall prevalence of alcohol use 
disorder to be 2.6% for Medicare recipients suggesting higher rates of alcohol use disorder in 
the head and neck cancer population (Centers for Medicare and Medicaid Services, 2017). 
Differences were found in prevalence of alcohol use disorder between those with and without 
preexisting depression. However, no differences were found in substance use disorders 
between patients that did and did not develop depression after diagnosis, regardless of their 
depression history. The lack of difference in substance use following cancer diagnosis suggests a 
lack of association between substance use and depression in this sample, however the 
prevalence of substance use shown in this data was likely not representative of the entire head 
and neck cancer population. This study was limited to reports of substance use disorders based 
on diagnostic codes which do not account for other types of substance use beyond clinical 
diagnoses. Most likely a higher percentage of the sample had history of substance use which 
was not document with Medicare codes and could not be accounted for in these analyses.  
This study had limitations based on the data set used for analyses. The SEER-Medicare 
database only offers diagnostic codes for identification of depression, comorbidities, and 
substance use. Previous research has shown higher estimates of prevalence and incidence of 
depression, substance use, and other comorbid conditions which suggests that diagnostic codes 
used in the SEER-Medicare database do not account for all forms of these diseases. 
Additionally, this sample only included individuals strictly relying on Medicare for their health 
care. According to the AARP Public Policy Institute (2009), over 90% of Medicare beneficiaries 
have supplemental insurance coverage and those individuals would not be accounted for in 
these analyses. This sample also only included individuals over the age of 67 so, interpretation 
is limited to older patients and should not be generalized to younger populations of head and 
neck cancer patients. Based on the limitations associated with SEER-Medicare data, more 
research needs to be done with less restrictive samples to further assess the impacts of 
comorbidity and substance use on depression in head and neck cancer patients. Further 
research should aim to include substance use information beyond claim data and an increased 
variety of comorbid conditions to get a more well-rounded view of the burdens on head and 
neck cancer patients.  
  
Table 1. Demographics by depression status prior to HNC diagnosis. 
  Depression (N=375) No Depression (N=3158)  
Variable Count % Count % p-value 
Age     0.0425 
 67-69 61 16.3% 671 21.3%  
 70-74 108 28.8% 899 28.5%  
 75-79 75 20.0% 696 22.0%  
 80-84 70 18.7% 484 15.3%  
 85+ 61 16.3% 408 12.9%  
Gender     <0.0001 
 Male 203 54.1% 2133 67.5%  
 Female 172 45.9% 1025 32.5%  
Race     0.0014 
 Non-Hispanic White 326 86.9% 2533 80.2%  
 Other 49 13.1% 625 19.8%  
% of Census Tract with 4 Year 
College Degree 
    
0.1845 
 0-33% 254 67.73% 2260 71.56%  
 34+% 93 24.80% 723 22.89%  
 Unknown 28 7.47% 175 5.54%  
Marital Status     0.0001 
 Married/Living as Married 152 40.5% 1642 52.0%  
 Divorced/Separated 43 11.5% 284 9.0%  
 Single 32 8.5% 274 8.7%  
 Widowed 128 34.1% 775 24.5%  
 Unknown 20 5.3% 183 5.8%  
Median Income (census tract)     0.9341 
 <$35,000 or Missing 124 33.1% 1005 31.8%  
 $35,000-$44,999 87 23.2% 723 22.9%  
 $45,000-$59,999 80 21.3% 714 22.6%  
 $60,000+ 84 22.4% 716 22.7%  
Cancer Stage     0.1805 
 Unstaged 150 40.0% 1394 44.1%  
 In Situ/Localized 84 22.4% 657 20.8%  
 Regional 102 27.2% 865 27.4%  
 Distant 39 10.4% 242 7.7%  
Comorbidity Group     <0.0001 
 0 69 18.4% 1186 37.6%  
 1 72 19.2% 896 28.4%  
 2 75 20.0% 486 15.4%  
 3 66 17.6% 291 9.2%  
 4+ 93 24.8% 299 9.5%  
Additional Depression DXa     N/A 
 Yes 167 44.5% - -  
 No 208 55.5% - -  
a Additional Depression DX indicates individuals with preexisting depression with at least one diagnosis of 
depression following head and neck cancer diagnosis 
  
Table 2. Comorbidities by depression status prior to HNC diagnosis. 
  Depression (N=375) No Depression (N=3158)  
Variable Count % Count % p-value 
Myocardial Infarction     0.0085 
 Yes 35 9.3% 181 5.7%  
 No 340 90.7% 2977 94.3%  
Congestive Heart Failure     <0.0001 
 Yes 122 32.5% 445 14.1%  
 No 253 67.5% 2713 85.9%  
Peripheral Vascular Disease     <0.0001 
 Yes 114 30.4% 559 17.7%  
 No 261 69.6% 2599 82.3%  
Cerebrovascular Disease     <0.0001 
 Yes 124 33.1% 508 16.1%  
 No 251 66.9% 2650 83.9%  
Dementia     <0.0001 
 Yes 56 14.9% 102 3.2%  
 No 319 85.1% 3056 96.8%  
Chronic Obstructive Pulmonary Disease     <0.0001 
 Yes 182 48.5% 978 31.0%  
 No 193 51.5% 2180 69.0%  
Rheumatologic Disease     0.0049 
 Yes 24 6.4% 104 3.3%  
 No 351 93.6% 3054 96.7%  
Peptic Ulcer Disease     0.0065 
 Yes 23 6.1% 100 3.2%  
 No 352 93.9% 3058 96.8%  
Mild Liver Disease     0.0289 
 Yes 24 6.4% 124 3.9%  
 No 351 93.6% 3034 96.1%  
Diabetes (Complicated)     0.0030 
 Yes 33 8.8% 153 4.8%  
 No 342 91.2% 3005 95.2%  
Diabetes (Non-complicated)     0.0042 
 Yes 108 28.8% 698 22.1%  
 No 267 71.2% 2460 77.9%  
Hemiplegia/Paraplegia     <0.0001 
 Yes 13 3.5% 25 0.8%  
 No 362 96.5% 3133 99.2%  
Moderate/Severe Renal Disease     0.0009 
 Yes 37 9.9% 166 5.3%  
 No 338 90.1% 2992 94.7%  
Moderate/Severe Liver Disease     0.4296 
 Yes 1 0.3% 4 0.1%  
 No 374 99.7% 3154 99.9%  
AIDS     0.2010 
 Yes 1 0.3% 1 >0.1%  
 No 374 99.7% 3157 <99.9%  
 
  
Table 2a. Substance use disorders by depression status prior to HNC diagnosis. 





Variable Count % Count % p-value 
Alcohol     0.0057 
 Yes 31 8.3% 145 4.7%  
 No 344 91.7% 2942 95.3%  
Tobacco     0.3025 
 Yes 41 10.9% 285 9.2%  
 No 334 89.1% 2802 90.8%  
Other Drugs     0.0862 
 Yes 4 1.1% 12 0.4%  
 No 371 98.9% 3075 99.6%  
b 71 patients missing substance use data 
 
  
Table 3. Multivariate logistic regression of depression prior to HNC diagnosis. 
Variable OR 95% CI p-value 
Gender    <0.0001 
 Male REF - -  
 Female 1.88 1.50 2.35  
Race/Ethnicity    0.0006 
 Non-Hispanic White REF - -  
 Other 0.57 0.41 0.79  
Comorbidity Group    <0.0001 
 0 REF - -  
 1 1.28 0.91 1.81  
 2  2.51 1.78 3.55  
 3 3.79 2.63 5.46  
 4+ 5.32 3.78 7.49  
Alcohol    0.0017 
 Yes 1.97 1.29 3.01  




Table 4. Demographics for patients with preexisting depression by status of additional depression 
diagnoses following HNC diagnosis. 





Variable Count % Count % p-value 
Age     0.3137 
 67-69 27 16.2% 34 16.4%  
 70-74 57 34.1% 51 24.5%  
 75-79 32 19.2% 43 20.7%  
 80-84 27 16.2% 43 20.7%  
 85+ 24 14.4% 37 17.8%  
Gender     0.8349 
 Male 89 53.3% 114 54.8%  
 Female 78 46.7% 94 45.2%  
Race     0.0031 
 Non-Hispanic White 155 92.8% 171 82.2%  
 Other 12 7.2% 37 17.8%  
% of Census Tract with 4 Year 
College Degree 
    
0.2189 
 0-33% 109 65.3% 145 69.7%  
 34+% 48 28.7% 45 21.6%  
 Unknown 10 6.0% 18 8.7%  
Marital Status     0.7952 
 Married/Living as Married 64 38.3% 88 42.3%  
 Divorced/Separated 21 12.57% 22 10.6%  
 Single 17 10.2% 15 7.2%  
 Widowed 56 33.5% 72 34.6%  
 Unknown 9 5.4% 11 5.3%  
Median Income (census tract)     0.9733 
 <$35,000 or Missing 55 32.9% 69 33.2%  
 $35,000-$44,999 40 24.0% 47 22.6%  
 $45,000-$59,999 34 20.4% 46 22.1%  
 $60,000+ 38 22.7% 46 22.1%  
Cancer Stage     0.2988 
 Unstaged 62 37.1% 88 42.3%  
 In Situ/Localized 45 27.0% 39 18.7%  
 Regional 44 26.3% 58 27.9%  
 Distant 16 9.6% 23 11.1%  
Comorbidity Group     0.4778 
 0 36 21.6% 33 15.9%  
 1 33 19.8% 39 18.8%  
 2 34 20.4% 41 19.7%  
 3 29 17.4% 37 17.8%  
 4+ 35 21.0% 58 27.9%  
 
  
Table 5. Comorbidities for patients with preexisting depression by status of additional depression diagnoses 
following HNC diagnosis. 





Variable Count % Count % p-value 
Myocardial Infarction     0.0203 
 Yes 9 5.4% 26 12.5%  
 No 158 94.6% 182 87.5%  
Congestive Heart Failure     0.6577 
 Yes 52 31.1% 70 33.7%  
 No 115 68.9% 138 66.3%  
Peripheral Vascular Disease     0.4988 
 Yes 54 32.3% 60 28.9%  
 No 113 67.7% 148 71.1%  
Cerebrovascular Disease     0.3780 
 Yes 51 30.5% 73 35.1%  
 No 116 69.5% 135 64.9%  
Dementia     0.5628 
 Yes 27 16.2% 29 13.9%  
 No 140 83.8% 179 86.1%  
Chronic Obstructive Pulmonary Disease     0.5347 
 Yes 78 46.7% 104 50.0%  
 No 89 53.3% 104 50.0%  
Rheumatologic Disease     0.3972 
 Yes 13 7.8% 11 5.3%  
 No 154 92.25 197 94.7%  
Peptic Ulcer Disease     0.3907 
 Yes 8 4.8% 15 7.2%  
 No 159 95.2% 193 92.8%  
Mild Liver Disease     0.8343 
 Yes 10 6.0% 14 6.7%  
 No 157 94.0% 194 93.3%  
Diabetes (Complicated)     0.2018 
 Yes 11 6.6% 22 10.6%  
 No 156 93.4% 186 89.4%  
Diabetes (Non-complicated)     0.0394 
 Yes 39 23.4% 69 33.2%  
 No 128 76.6% 139 66.8%  
Hemiplegia/Paraplegia     0.5752 
 Yes 7 4.2% 6 2.9%  
 No 160 95.8% 202 97.1%  
Moderate/Severe Renal Disease     0.0245 
 Yes 10 6.0% 27 13.0%  
 No 157 94.0% 181 87.0%  
Moderate/Severe Liver Disease     0.4453 
 Yes 1 0.6% 0 0%  
 No 166 99.4% 208 100%  
AIDS     0.4453 
 Yes 1 0.6% 0 0%  
 No 166 99.4% 208 100%  
  
Table 5a. Substance use disorders for patients with preexisting depression by status of 
additional depression diagnoses following HNC diagnosis. 






Variable Count % Count % p-value 
Alcohol     1.0000 
 Yes 14 8.4% 17 8.2%  
 No 153 91.6% 191 91.8%  
Tobacco     0.6188 
 Yes 20 12.0% 21 10.1%  
 No 147 88.0% 187 89.9%  
Other Drugs     0.6320 
 Yes 1 0.6% 3 1.4%  




Table 6. Demographics by depression status following HNC diagnosis, excluding those with preexisting 
depression. 
  Depression (N=281) No Depression (N=2877)  
Variable Count % Count % p-value 
Age     0.0111 
 67-69 52 18.5% 619 21.5%  
 70-74 99 35.2% 800 27.8%  
 75-79 52 18.5% 644 22.4%  
 80-84 52 18.5% 432 15.0%  
 85+ 26 9.3% 382 13.3%  
Gender     0.0027 
 Male 167 59.4% 1966 68.3%  
 Female 114 40.6% 911 31.7%  
Race     0.4327 
 Non-Hispanic White 231 82.2% 2302 80.0%  
 Other 50 17.8% 575 20.0%  
% of Census Tract with 4 Year 
College Degree 
    
0.3601 
 0-33% 197 70.1% 2072 71.7%  
 34+% 72 25.6% 654 22.6%  
 Unknown 12 4.3% 165 5.7%  
Marital Status     0.1884 
 Married/Living as Married 131 46.6% 1511 52.5%  
 Divorced/Separated 23 8.2% 261 9.1%  
 Single 29 10.3% 245 8.5%  
 Widowed 83 29.5% 692 24.1%  
 Unknown 15 5.3% 168 5.8%  
Median Income (census tract)     0.8207 
 <$35,000 or Missing 84 29.9% 921 32.0%  
 $35,000-$44,999 63 22.4% 660 23.0%  
 $45,000-$59,999 69 24.6% 645 22.4%  
 $60,000+ 65 23.1% 651 22.6%  
Cancer Stage     0.2895 
 Unstaged 115 40.9% 1279 44.5%  
 In Situ/Localized 54 19.2% 603 21.0%  
 Regional 85 30.3% 780 27.1%  
 Distant 27 9.6% 215 7.5%  
Comorbidity Group     0.0734 
 0 102 36.3% 1084 37.7%  
 1 67 23.8% 829 28.8%  
 2 57 20.3% 429 14.9%  
 3 31 11.0% 260 9.0%  
 4+ 24 8.5% 275 9.6%  
 
  
Table 7. Comorbidities by depression status following HNC diagnosis, excluding those with preexisting depression. 
  Depression (N=281) No Depression (N=2877)  
Variable Count % Count % p-value 
Myocardial Infarction     0.5907 
 Yes 18 6.4% 163 5.7%  
 No 263 93.6% 2714 94.3%  
Congestive Heart Failure     0.1788 
 Yes 47 16.7% 398 13.8%  
 No 234 83.3% 2479 86.2%  
Peripheral Vascular Disease     0.6231 
 Yes 53 18.9% 506 17.6%  
 No 228 81.1% 2371 82.4%  
Cerebrovascular Disease     0.4973 
 Yes 49 17.4% 459 16.0%  
 No 232 82.6% 2418 84.0%  
Dementia     0.7229 
 Yes 10 3.6% 92 3.2%  
 No 271 96.4% 2785 96.8%  
Chronic Obstructive Pulmonary Disease     0.3447 
 Yes 94 33.5% 884 30.7%  
 No 187 66.5% 1993 69.3%  
Rheumatologic Disease     1.0000 
 Yes 9 3.2% 95 3.3%  
 No 272 96.8% 2782 96.7%  
Peptic Ulcer Disease     0.7197 
 Yes 10 3.6% 90 3.1%  
 No 271 96.4% 2787 96.9%  
Mild Liver Disease     0.8724 
 Yes 10 3.6% 114 4.0%  
 No 271 96.4% 2763 96.0%  
Diabetes (Complicated)     0.7708 
 Yes 12 4.3% 141 4.9%  
 No 269 95.7% 2736 95.1%  
Diabetes (Non-complicated)     0.7636 
 Yes 64 22.8% 634 22.0%  
 No 217 77.2% 2243 78.0%  
Hemiplegia/Paraplegia     0.4831 
 Yes 3 1.1% 22 0.8%  
 No 278 98.9% 2855 99.2%  
Moderate/Severe Renal Disease     0.5742 
 Yes 12 4.3% 154 5.3%  
 No 269 95.7% 2723 94.7%  
Moderate/Severe Liver Disease     1.0000 
 Yes 0 0% 4 0.1%  
 No 281 100% 2873 99.9%  
AIDS     1.0000 
 Yes 0 0% 1 >0.1%  
 No 281 100% 2876 >99.9%  
 
  
Table 7a. Substance use disorders by depression status following HNC diagnosis, excluding 
those with preexisting depression.  





Variable Count % Count % p-value 
Alcohol     0.7670 
 Yes 14 5.0% 131 4.7%  
 No 267 95% 2689 95.3%  
Tobacco     0.1930 
 Yes 32 11.4% 253 9.0%  
 No 249 88.6% 2567 91.0%  
Other Drugs     0.0877 
 Yes 3 1.1% 9 0.3%  
 No 278 98.9% 2811 99.7%  
c 71 patients missing substance use data 
 
  
Table 8. Multivariate logistic regression of depression following HNC diagnosis. 
Variable OR 95% CI p-value 
Gender    0.0023 
 Male REF - -  
 Female 1.49 1.15 1.92  
Age Group    0.0089 
 67-69 REF - -  
 70-74 1.43 1.01 2.04  
 75-79 0.92 0.62 1.38  
 80-84 1.32 0.88 1.97  
 85+ 0.72 0.44 1.18  
 
  




Total patients with HNC from 2004-2005: 
12,175 
Patients with HNC as only cancer 
diagnosis: 9,224 
Patients removed for not having HNC as 
only cancer diagnosis: 2,951 




Total patients with HNC from 2004-2005: 
12,175 
Patients removed for age below 67 at time 
of HNC diagnosis: 4,315 




Total patients with HNC from 2004-2005: 
12,175 
Patients removed for inconsistent 
enrollment in Medicare Parts A and B: 151 
Final Sample for depression analysis prior 
to HNC diagnosis: 3,533
 
 
Total patients with HNC from 2004-2005: 
12,175 
Patients removed for enrollment in an 
HMO during the study period: 1,225 
Final sample for depression analysis 
following HNC diagnosis: 3,158 
Patients removed for diagnosis with 
depression prior to HNC diagnosis: 375 
Final sample for additional depression 
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